Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence
Allurion Technologies, Inc. (ALUR)
Company Research
Source: Business Wire
Average Total Weight Loss of 23% With 14% Increase in Lean Body Mass After 12 MonthsAll patients remained adherent to tirzepatide for the duration of the study NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced initial results on the combination of the Allurion Program with low-dose tirzepatide therapy to optimize muscle mass and GLP-1 adherence.76 patients treated with the Allurion Smart Capsule were started on low-dose tirzepatide after completing their first 45 days of balloon therapy. The starting dose of tirzepatide was 2.5mg and increased to no greater than 5.0mg over the subsequent 2 months, considerably lower than standard dosing which can increase to 15mg. Tirzepatide therapy was continued for 8 months and final results were measured 2 months after discontinuation, for a total follow-up period of 12 months. Patients were followed using the AI-powered Virtual
Show less
Read more
Impact Snapshot
Event Time:
ALUR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALUR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALUR alerts
High impacting Allurion Technologies, Inc. news events
Weekly update
A roundup of the hottest topics
ALUR
News
- New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention AloneBusiness Wire
- Allurion Technologies (NYSE:ALUR) had its "neutral" rating reaffirmed by analysts at Chardan Capital. They now have a $2.50 price target on the stock.MarketBeat
- Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight LossBusiness Wire
- Allurion Technologies Inc (ALUR) Q3 2025 Earnings Call Highlights: Strategic Restructuring and ... [Yahoo! Finance]Yahoo! Finance
- Allurion Technologies Inc. (ALUR) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
ALUR
Earnings
- 5/14/25 - Beat
ALUR
Sec Filings
- 12/2/25 - Form 144
- 11/26/25 - Form D
- 11/25/25 - Form DEFA14A
- ALUR's page on the SEC website